Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data
G.B. Migliori, S. Ahuja, D. Ashkin, M. Avendano, R. Banerjee, M. Bauer, J. Bayona, M. Becerra, A. Benedetti, M. Burgos, R. Centis, E.D. Chan, C.Y. Chiang, H. Cox, L. D‘Ambrosio, K. DeRiemer, N.H. Dung, D. Enarson, K. Flanagan, J. Flood, M.L. Garcia-Garcia, N. Gandhi, R. Granich, M.G. Hollm-Delgado, T.H. Holtz, M. Iseman, L. Jarlsberg, S. Keshavjee, H.R. Kim, W.J. Koh, J. Lancaster, C. Lange, W.C.M. de Lange, V. Leimane, C.C. Leung, J. Li, S. Mishustin, C. Mitnick, M. Narita, P. O‘Riordan, M. Pai, D. Palmero, S.K. Park, G. Pasvol, J. Pena, C. Pérez-Guzmán, M. Quelapio, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, H.S. Schaaf, K.J. Seung, L. Shah, T.S. Shim, S.S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, G. Sotgiu, M.J. Strand, P. Tabarsi, T.E. Tupasi, R. van Altena, M. Van der Walt, T.S. Van der Werf, M.H. Vargas, P. Viiklepp, J. Westenhouse, W.W. Yew, J.J. Yim, D. Menzies (Tradate, Italy; Long Island City, Lantana, Rochester, Hanover, Boston, Albuquerque, Denver, Davis, Richmond, Bronx, Atlanta, San Francisco, New York, Seattle, United States Of America; Toronto, Montreal, Canada; Paris, France; Taipei City, Taiwan; Cape Town, Pretoria, Tygerberg, South Africa; Ho Chi Minh City, Viet Nam; Tasmania, Australia; Cuernavaca, Aguascalientes, Mexico City, Mexico; Geneva, Switzerland; Seoul, Masan City, Republic Of Korea; Borstel, Germany; Groningen, Netherlands; Upeslejas, Latvia; Hong Kong, Hong Kong; Tomsk, Russian Federation; London, United Kingdom; Buenos Aires, Argentina; Madrid, Spain; Makati, Philippines; , ; Tokyo, Japan; Tehran, Islamic Republic Of Iran; Tallinn, Estonia)
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Session: Pros and cons of MDR- and XDR-TB treatment
Session type: Oral Presentation
Number: 4286
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G.B. Migliori, S. Ahuja, D. Ashkin, M. Avendano, R. Banerjee, M. Bauer, J. Bayona, M. Becerra, A. Benedetti, M. Burgos, R. Centis, E.D. Chan, C.Y. Chiang, H. Cox, L. D‘Ambrosio, K. DeRiemer, N.H. Dung, D. Enarson, K. Flanagan, J. Flood, M.L. Garcia-Garcia, N. Gandhi, R. Granich, M.G. Hollm-Delgado, T.H. Holtz, M. Iseman, L. Jarlsberg, S. Keshavjee, H.R. Kim, W.J. Koh, J. Lancaster, C. Lange, W.C.M. de Lange, V. Leimane, C.C. Leung, J. Li, S. Mishustin, C. Mitnick, M. Narita, P. O‘Riordan, M. Pai, D. Palmero, S.K. Park, G. Pasvol, J. Pena, C. Pérez-Guzmán, M. Quelapio, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, H.S. Schaaf, K.J. Seung, L. Shah, T.S. Shim, S.S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, G. Sotgiu, M.J. Strand, P. Tabarsi, T.E. Tupasi, R. van Altena, M. Van der Walt, T.S. Van der Werf, M.H. Vargas, P. Viiklepp, J. Westenhouse, W.W. Yew, J.J. Yim, D. Menzies (Tradate, Italy; Long Island City, Lantana, Rochester, Hanover, Boston, Albuquerque, Denver, Davis, Richmond, Bronx, Atlanta, San Francisco, New York, Seattle, United States Of America; Toronto, Montreal, Canada; Paris, France; Taipei City, Taiwan; Cape Town, Pretoria, Tygerberg, South Africa; Ho Chi Minh City, Viet Nam; Tasmania, Australia; Cuernavaca, Aguascalientes, Mexico City, Mexico; Geneva, Switzerland; Seoul, Masan City, Republic Of Korea; Borstel, Germany; Groningen, Netherlands; Upeslejas, Latvia; Hong Kong, Hong Kong; Tomsk, Russian Federation; London, United Kingdom; Buenos Aires, Argentina; Madrid, Spain; Makati, Philippines; , ; Tokyo, Japan; Tehran, Islamic Republic Of Iran; Tallinn, Estonia). Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data. Eur Respir J 2012; 40: Suppl. 56, 4286
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 656s Year: 2004
Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2013; 42: 169-179 Year: 2013
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002
A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017
Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007